Bevacizumab in Combination with Irinotecanand Capecitabine as First-Line Treatment for MCRC - Efficacy and Safety (Meeting Abstract)

Naslov

Bevacizumab in Combination with Irinotecanand Capecitabine as First-Line Treatment for MCRC - Efficacy and Safety (Meeting Abstract)

Identifikator

/unibl/sci/idNaucniRad:13157
info:doi/doi: 10.1093/annonc/mdu165.175

Tip

Pronađite slične unoseConference Paper
Pronađite slične unosetext

Datum

Pronađite slične unose2014

Bibliografski citat

S. Jungić, G. Kecman Malčić, I. Rakita, D. Jovanović, R. Gajanin, Z. Marić, Z. Gojković, B. Tubić, Bevacizumab in Combination with Irinotecanand Capecitabine as First-Line Treatment for MCRC - Efficacy and Safety (Meeting Abstract), Annals of Oncology, Vol. 25(2), pp. 68 - 68, 2014

Referenca

http://annonc.oxfordjournals.org/content/25/suppl_2/ii68.3.full

Početna stranica

68

Krajnja stranica

68

Prezentovano

This article appears in:ESMO 16th World Congress on Gastrointestinal Cancer, 25–28 June 2014, Barcelona, Spain

Je dio

Annals of Oncology, Vol. 25(2)

Lista autora

Pronađite slične unoseSaša Jungić
Pronađite slične unoseGordana Kecman Malčić
Pronađite slične unoseIvanka Rakita
Pronađite slične unoseDušan Jovanović
Pronađite slične unoseRadoslav Gajanin
Pronađite slične unoseZdravko Marić
Pronađite slične unoseZdenka Gojković
Pronađite slične unoseBiljana Tubić

Position: 5273 (37 views)